Immuno-oncology

Oral

Alloresponse to Anti-leukemia (cll): Reassessing the Role of cd4+ T Cells

Wednesday, June 14
6:15 PM - 7:45 PM

Tumor-specific mutations are ideal targets for cancer immunotherapy as there is a lack of expression in healthy tissue; potentially they can be recognized as neo-antigens by the mature T-cell repertoire which can reject the tumor.
Our aim was to characterize neopeptides of CLL-patient's tumors from the protein-encoding sequences of 500 genomes (exomes) that can be recognized by T cells through their binding affinities to HLA molecules.
Neopeptide missense mutations was used to epitopic prediction: concatamers (overlapping sequences) of these neopeptides was analyzed for epitopic predictive binding in all HLA molecules.


At last, by co-relating these peptides with the specific HLA typing from each patient we define most reactive neopeptides to test in vitro.

E. Azucena González-Navarro

Hospital Clínic Barcelna

Presentation(s):

    Send Email for E. Azucena González-Navarro

    Jordi Coll

    IES Europa

    Presentation(s):

      Send Email for Jordi Coll

      Carles Serra

      Hospital Clínic Barcelona

      Presentation(s):

        Send Email for Carles Serra

        Elias Campo

        Hospital Clínic Barcelona

        Presentation(s):

          Send Email for Elias Campo

          Manel Juan

          Hospital Clínic Barcelona

          Presentation(s):

            Send Email for Manel Juan


            Assets

            Alloresponse to Anti-leukemia (cll): Reassessing the Role of cd4+ T Cells



            Attendees who have favorited this

            Send Email for Alloresponse to Anti-leukemia (cll): Reassessing the Role of cd4+ T Cells